Lactobacillus lactis

Lactobacillus lactis: Encyclopedic Reference

Nomenclature, Identity, and Taxonomic Notes

The name Lactobacillus lactis has a complex and evolving history in microbial taxonomy, and its accurate use requires careful disambiguation. In current scientific nomenclature, the organism originally described under this name is formally designated Lactobacillus delbrueckii subsp. lactis. The NCBI Taxonomy database lists Lactobacillus delbrueckii subsp. lactis (Orla-Jensen 1919) Weiss et al. 1984, with the basionym Lactobacillus lactis (Orla-Jensen 1919) Bergey et al. 1934 (Approved Lists 1980), and the type strain deposited as ATCC 12315, DSM 20072, and JCM 1248, among others. The species name traces to early 20th-century descriptions of thermophilic lactic acid bacteria isolated from dairy environments.

In dietary supplement contexts and much of the food-industry literature, Lactobacillus lactis is also frequently used as a colloquial shorthand for Lactococcus lactis, a mesophilic lactic acid bacterium that was itself reclassified out of the Lactobacillus genus. Lactococcus lactis is one of the best-known and well-characterized species of lactic acid bacteria (LAB) and serves as a model organism for studying LAB. Although Lactobacillus delbrueckii subsp. lactis and Lactococcus lactis are taxonomically distinct, they share overlapping common names, similar ecological niches, and comparable functional properties; this article covers both organisms under the umbrella term "Lactobacillus lactis" as it appears in the supplement and functional food literature, clearly noting distinctions where they are scientifically relevant.

The genus Lactobacillus comprised 261 species as of March 2020 and was found to be extremely diverse at phenotypic, ecological, and genotypic levels. A major 2020 taxonomic revision evaluated Lactobacillaceae and Leuconostocaceae on the basis of whole genome sequences, assessing parameters including core genome phylogeny, pairwise average amino acid identity, clade-specific signature genes, physiological criteria, and ecology of the organisms. Based on this polyphasic approach, the genus Lactobacillus was reclassified into 25 genera, including the emended genus Lactobacillus — which retains host-adapted organisms of the Lactobacillus delbrueckii group — and 23 novel genera.

Within this revised classification, Lactobacillus delbrueckii subsp. lactis remains within the retained emended genus Lactobacillus, as it belongs to the host-adapted Lactobacillus delbrueckii group. Among the 42 species retained in Lactobacillus, L. delbrueckii subsp. lactis is particularly important for the commercial production of fermented products such as yogurt and cheese.

Key synonyms and related names in scientific and commercial use:

• Lactobacillus lactis (Orla-Jensen 1919) Bergey et al. 1934 — historical name, approved 1980
• Lactobacillus delbrueckii subsp. lactis — current formal name for the thermophilic dairy organism
• Lactococcus lactis — closely related mesophilic organism, formerly classified within Streptococcus and then Lactobacillus, now in its own genus; commonly encountered under the colloquial label "Lactobacillus lactis" in older and commercial literature
• Thermobacterium lactis (Orla-Jensen 1919) — obsolete effective name

Both organisms are Gram-positive, non-spore-forming, facultative anaerobes belonging to the order Lactobacillales, family Lactobacillaceae. Lactobacillus refers to a group of lactic acid–producing Gram-positive rods that are obligate and facultative anaerobes in the human gastrointestinal and genitourinary tracts.

Natural Sources and Ecological Distribution

Being part of the natural flora of a range of food products like raw milk, fermented dairy products, fruits, vegetables, and meat products, lactic acid bacteria also serve as starters for a number of fermented food products, either to enhance quality or to add health benefits.

Lactobacillus species, restricted by fastidious growth requirements, occupy nutrient-rich habitats which can be categorized into fermented or spoiled foods and animal feed, the environment including the surface of plants, soil, and the body of invertebrate and vertebrate animals.

Lactococcus lactis is the main constituent of dairy starter culture systems used worldwide for the production of numerous fermented dairy products, including cheeses of both artisanal and commercial origin, and fermented milks such as buttermilk and sour cream. Lactococcus lactis is an organism of substantial economic importance, used extensively in the production of fermented foods, and is widely held to have evolved from plant strains.

Lactobacillus delbrueckii is a key lactic acid bacterium widely used in dairy fermentation, particularly in the production of yogurt, cheese, and kefir. Its metabolic activities — such as efficient lactose utilization, rapid acidification, and high proteolytic activity — make it an indispensable starter culture in the dairy industry.

Lactococcus lactis is the lactic acid bacterium most widely used as a primary fermentation starter in the dairy industry, and is routinely employed in the production of matured cheese, unripened cheeses such as cream cheese and cottage cheese, fermented milk products, sour cream, and fermented butter.

Traditional and Historical Use

The use of lactic acid bacteria in the fermentation process to produce fermented foods has a long history. LAB are beneficial microorganisms known for their health-promoting characteristics. People from different cultural backgrounds, and from across the globe, have been consuming fermented dairy products for millennia.

For a very long time, L. lactis has been used in milk fermentation, both in well-monitored industrial settings and on a small scale in traditional operations. It is a vital microorganism in the dairy food fermentation industry due to its role in acidification, flavor development, and the creation of various dairy products, including cheese, fermented butter, and others.

The lactic acid fermentation process — which includes the activity of these organisms — has been practiced across virtually all traditional food cultures. The diets of every traditional society have included some kind of lacto-fermented food; Europeans consume lacto-fermented dairy, sauerkraut, grape leaves, herbs, and root vegetables, while the Alaskan Inuit ferment fish and sea mammals. Eastern cultures are known for pickled vegetables, sauces, and kimchi in particular, while farming societies in central Africa are known for porridges made from soured grains.

Lactobacillus organisms were first formally described in 1901 with Lactobacillus delbrueckii, a species indispensable in yogurt production, and the field grew exponentially since the beginning of the 21st century thanks to new genetic sequencing methods. The deliberate use of specific lactic acid bacterial cultures in dairy fermentation was standardized and formalized in the early 20th century by the dairy industry, though the underlying fermentative processes had been exploited for thousands of years before the organisms were identified.

In traditional medicine and dietary practice, fermented milk products containing these organisms were consumed across Asia, the Middle East, Europe, and Africa for their perceived digestive and nutritive benefits. Lactobacillus and Bifidobacterium strains have been widely used for a long time in the dairy and biotechnology industry in production of fermented dairy foods, in particular cheese and yogurt, and non-dairy products such as vegetables, beverages, and meats. They play key roles in food preservation and contribute to the development of food texture and flavor with health-promoting properties.

Key Constituents and Active Compounds

During fermentation, LAB have the capacity to produce significant amounts of bioactive substances, such as peptides, bacteriocins, lactic acid, exopolysaccharides (EPSs), enzymes, and others. The major bioactive categories produced by Lactobacillus lactis (including both L. delbrueckii subsp. lactis and Lactococcus lactis) are as follows:

Bacteriocins

Lactococcus species generate more than 40 peculiar bacteriocins — antimicrobial proteins synthesized by ribosomes. These bacteriocins mainly belong to two classes: Class I includes post-translationally modified, small (<10 kDa), heat-stable peptides such as nisin A; Class II involves non-modified, small (<10 kDa), mainly heat-stable peptides such as lactococcin G. Nisin A is generated by L. lactis and contains 34 amino acids.

The bacteriocin nisin is naturally produced by Lactococcus lactis as an inactive prepeptide that is modified posttranslationally, resulting in five (methyl-)lanthionine rings characteristic for class Ia bacteriocins. Export and proteolytic cleavage of the leader peptide results in release of active nisin. By targeting the universal peptidoglycan precursor lipid II, nisin has a broad target spectrum including important human pathogens such as Listeria monocytogenes and methicillin-resistant Staphylococcus aureus.

Nisin shows a wide spectrum of antimicrobial activity that is promoted by a dual mechanism of action: interfering with cell wall synthesis and promoting pore formation in the cell membrane. Nisin is an antimicrobial peptide belonging to the lantibiotic class of bacteriocins (Class I) and has been employed as a food preservative in over 50 countries. Lantibiotics are characterized by the presence of unusual amino acid residues, including the lanthionines which give these peptides their name.

Nisin A was first discovered in 1928 in fermenting milk cultures. Beyond nisin, other bacteriocins produced from the genus Lactococcus are also of economic importance. Lacticin 3147 is an example of a bacteriocin derived from Lactococcus spp., which works efficiently across a broad array of pH values and comprises a wide antimicrobial action spectrum over Gram-positive bacteria.

Exopolysaccharides (EPSs)

This bacterium produces a wide range of metabolites, including bacteriocins and exopolysaccharides (EPSs), which are high-molecular-weight biopolymers consisting of repeated monosaccharide units characterized by their large and complex structure. EPSs are associated with immune-modulatory activity, gut barrier reinforcement, and the characteristic textures of fermented dairy products.

Bioactive Peptides

L. delbrueckii contributes significantly to human health through the production of bioactive peptides (BAPs), extracellular polysaccharides (EPS), and other functional metabolites with antioxidant, anti-inflammatory, and immunomodulatory effects.

Lactic Acid

L. lactis plays a major role during the early stages of cheesemaking, since it quickly acidifies milk by metabolizing lactose into lactic acid. This lactic acid inhibits the growth of spoilage and pathogenic microorganisms, improving the shelf life and safety of the fermented end product.

Gamma-Aminobutyric Acid (GABA)

Several strains of Lactococcus lactis produce the inhibitory neurotransmitter GABA through glutamate decarboxylase (GAD) activity. L. lactis has been demonstrated to exert potent anti-inflammatory activity attenuating colitis in vivo, and the well-characterized strain NCDO2118, in addition to its probiotic properties, is considered an efficient GABA producer among the species. Gut-derived GABA can activate GABA receptors in the enteric nervous system (ENS), thereby modulating intestinal motility, reducing neuronal sensitivity, and exerting anti-inflammatory effects. However, oral GABA is limited by poor blood-brain barrier permeability and rapid absorption in the proximal intestine, restricting its availability to colonic and local immune targets. In contrast, GABA-producing probiotics can synthesize GABA in situ, enabling localized and sustained release within the gut, thereby more effectively modulating ENS activity.

Mechanisms of Action

Gut Microbiota Modulation

Probiotic microorganisms, including strains of Lactobacillus delbrueckii subsp. lactis, can regulate gut microbial communities and support host metabolic and immune homeostasis. Various strains within the Lactobacillus genus have demonstrated health-promoting functions such as enhancing intestinal integrity and modulating systemic physiology.

Immunomodulation via NF-κB Inhibition

Among characterized strains, L. delbrueckii subsp. lactis CIDCA 133 has demonstrated immunomodulation by inhibition of the NF-κB signaling pathway; tolerance to high concentrations of bile salts; no hemolytic or mucin degradation activity; and no adverse effects on clinical and histopathological parameters in mice.

Competitive Exclusion and Pathogen Inhibition

The strain CIDCA 133 has been shown to inhibit pathogens including Escherichia coli, Bacillus cereus, Citrobacter rodentium, and Salmonella Typhimurium. Probiotics impede the adhesion and proliferation of harmful bacteria by competing for epithelial cell attachment sites, vital nutrients, and monosaccharides, hindering the growth of pathogenic organisms and decreasing their population within the gastrointestinal tract.

Antioxidant Activity

GC-MS analysis of Lactococcus lactis strains has revealed bioactive metabolites reported in the literature to have immunomodulatory effects, antioxidant properties, collagen synthesis activity, and wound healing properties. The presence of these compounds was further affirmed by FT-IR spectroscopy.

Gut–Brain Axis Modulation

Evidence suggests that microbially produced neuroactive molecules, like γ-aminobutyric acid (GABA), can modulate the gut–brain axis. Natural strains of Lactococcus lactis were characterized for their GABA production and tested in vivo in rats for antinociceptive properties. L. lactis NCDO2118 significantly reduced visceral hypersensitivity induced by stress due to its glutamate decarboxylase (GAD) activity.

Anticancer Mechanisms (Preclinical)

Bacteriocins including nisin A and nisin Z drive apoptosis of cancer cells and show low toxicity toward normal cells, making them promising anticancer candidates. Bacteriocinogenic LAB and the bacteriocins they produce may also have an impact on modulation of the microbiota and immune system of the host.

Scientific Evidence by Area of Use

1. Gut Health and Digestive Function

Preclinical evidence (in vitro and animal models): Studies have demonstrated that L. delbrueckii subsp. lactis can reduce fasting blood glucose levels, inhibit the growth of pathogenic bacteria, and ameliorate ulcerative colitis. L. lactis has been demonstrated to exert potent anti-inflammatory activity attenuating colitis in vivo.

In an animal model study of irritable bowel syndrome (IBS), researchers screened Lactococcus lactis strains with varying GABA production and evaluated their effects on intestinal dysfunction and neurobehavioral abnormalities in an IBS mouse model, with a focus on GABAergic signaling and dose-dependent mechanisms. Three strains were selected; IBS was induced via Citrobacter rodentium infection and water avoidance stress; intestinal integrity, inflammation, histopathology, and behavior were assessed. GABA-producing strains alleviated intestinal dysfunction in IBS mice by reducing IL-6 gene expression and iNOS activity and upregulating claudin-2 (CLDN2). These findings are preclinical (mouse model); direct human translation has not yet been established.

Evidence strength: Preclinical (animal/in vitro). Human clinical evidence for gut disorders specifically is limited.

2. Cognitive Function and the Gut–Brain Axis

This is the most advanced area with respect to rigorous human clinical evidence for L. delbrueckii subsp. lactis specifically. Modulation of the gut–brain axis using probiotics presents a promising approach for enhancing cognitive function in mild cognitive impairment (MCI). In prior non-clinical research, Lactobacillus delbrueckii subsp. lactis CKDB001 exhibited potential to enhance cognitive function, and a clinical trial was conducted to assess its efficacy and safety in MCI.

A 12-week, randomized, double-blind, placebo-controlled, multi-center trial was performed in 100 participants aged 55–80 years. Subjects were randomly assigned to receive CKDB001 (n = 50, 5.0 × 10⁹ CFU/day) or placebo (n = 50). Efficacy and safety were evaluated at baseline and after 12 weeks.

Results showed that supplementation resulted in significantly greater improvements than placebo in the Alzheimer's Disease Assessment Scale–Cognition 13 (ADAS-Cog 13) total score, the memory sub-score, reaction time for Part A of the Trail Making Test, and word/color reaction times on the Stroop test.

Taxonomic and metabolomic profiling of fecal samples showed significantly greater changes in the relative abundance of beneficial microorganisms in the treatment group, with the most pronounced shifts at the family (Lactobacillaceae, Bifidobacteriaceae) and genus (Lactobacillus) levels. The treatment group also exhibited significantly higher fecal levels of indole-derived metabolites, including 5-hydroxyindole-3-acetic acid, indole-3-lactic acid, and indole-3-glycol.

Recent non-clinical studies suggest that microbiome-derived indole-3-lactic acid (ILA), produced by CKDB001, can activate the aryl hydrocarbon receptor (AhR), mitigate amyloid pathology, and thus improve cognitive function, providing a potential mechanistic link between modulation of the gut-brain axis and cognitive outcomes.

Safety assessments indicated the probiotic was safe and well-tolerated, with no clinically relevant changes in laboratory findings or adverse events.

Evidence strength: A single small (n=100) randomized controlled trial (RCT) with positive results at 12 weeks. This is encouraging but preliminary; replication in larger and longer trials is needed before firm conclusions can be drawn about clinical efficacy for MCI.

3. Metabolic Health and Obesity

Animal model research has investigated the strain L. delbrueckii subsp. lactis CKDB001 in metabolic contexts. In a high-fat diet (HFD) mouse model, treatment groups received a daily oral gavage of CKDB001 (1 × 10⁹ CFU in 200 µL sterile phosphate-buffered saline) for 12 weeks. Prior studies have demonstrated that L. delbrueckii subsp. lactis can reduce fasting blood glucose levels and ameliorate ulcerative colitis in preclinical models.

Important areas require further investigation to fully understand the efficacy as a potential probiotic supplement; future studies should focus on assessing the bioavailability in clinical settings and explore methods to enhance stability or absorption in the body.

Evidence strength: Preclinical only (mouse models). No completed human RCTs on metabolic outcomes for this specific subspecies are available in the current literature.

4. Immune Modulation and Oncology (Emerging)

A separate but related organism, Lactobacillus lactis strain GEN-001 (a live biotherapeutic product developed from L. lactis), has entered early-phase human clinical investigation as an immunomodulatory agent in oncology. Designated GEN-001, this strain is described as a live, purified, facultative anaerobic Gram-positive probiotic lactic acid bacterial strain with more than 1 × 10¹¹ CFU per container. GEN-001 has immunomodulatory activity and may have therapeutic benefits against cancer via activation of immune cells such as CD4 or CD8 T cells and natural killer cells, and through interactions with the chemotherapy drug oxaliplatin.

A Phase I/Ib, first-in-human, open-label, dose escalation and dose expansion study (NCT04601402) has been conducted to evaluate the safety, tolerability, biological and clinical activities of GEN-001 in combination with avelumab in patients with locally advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy, including an anti-PD-1 or anti-PD-L1 based therapy.

In preclinical research, L. lactis GEN3013 demonstrated inhibition of cell growth of various human and murine cancer cell lines in vitro. Consistent with these results, GEN3013 showed antitumor effects and enhanced the therapeutic efficacy of both chemotherapy and immunotherapy in syngeneic mice. The host immune system was activated both locally and systemically by the combinatorial treatment of GEN3013 with chemotherapy and immunotherapy, suggesting it could be utilized as a novel biotherapeutic agent for cancer treatment.

Data concerning the anti-proliferative effect of L. lactis strains in cancer contexts are limited; a soluble cell extract of a L. lactis ssp. lactis strain was shown to have an antiproliferative effect on the human stomach cancer cell line SNU-1.

Evidence strength: Predominantly preclinical (cell lines and animal models). Phase I human trials are ongoing or recently initiated; no published efficacy data from human oncology RCTs are available as of 2025–2026. This area should be regarded as highly preliminary.

5. Antimicrobial and Food Safety Applications

Bacteriocins derived from LAB have diverse potential applications, including the prevention of food infestation by harmful bacteria and their use as antibiotic alternatives in veterinary and medical use. The most commonly used bacteriocin is nisin, produced by L. lactis, and it is used as an antimicrobial for numerous pathogenic bacteria.

Cell-free supernatant from Lactococcus lactis A5 has shown inhibitory activities against both Gram-positive pathogens (Bacillus cereus and Staphylococcus aureus) and Gram-negative pathogens (Salmonella typhimurium). These activities are primarily of relevance to food preservation; their direct clinical application in human infectious disease has not been validated in human trials.

6. Bone Metabolism (Exploratory, Preclinical)

An exploratory in vitro study investigated L. delbrueckii subsp. lactis KUMS-Y33 on human adipose-derived mesenchymal stem cells. Results indicated the probiotic extract inhibits adipogenesis and significantly increases osteogenesis, suggesting a positive role in the prevention and treatment of bone aging, including conditions such as osteoporosis. However, total implications in the body will remain unclear as complex systemic factors limit the effects. It cannot be concluded which compound in the extract drives these trends. The extract requires future in vivo studies, and fractionation would provide more insight into the potential.

Evidence strength: Preliminary in vitro data only. No human clinical trials for bone health outcomes have been reported.

Body Systems and Health Areas of Association

• Gastrointestinal system: Colonization resistance, gut barrier reinforcement, anti-inflammatory effects on colitis, modulation of intestinal motility via GABA signaling (preclinical)
• Immune system: NF-κB pathway modulation, activation of CD4/CD8 T cells and NK cells, modulation of pro-inflammatory cytokines (IL-6, TNF), immunomodulatory bacteriocin activity (primarily preclinical)
• Neurological/central nervous system (gut–brain axis): GABA production modulating enteric nervous system and visceral sensitivity; indole-3-lactic acid and aryl hydrocarbon receptor (AhR) activation with potential relevance to cognitive function (one RCT; preclinical mechanistic evidence)
• Metabolic system: Reported reduction in fasting blood glucose, effects on lipid metabolism and hepatic steatosis in animal models (preclinical)
• Oncology (experimental): Bacteriocin-mediated cancer cell apoptosis; synergy with checkpoint inhibitor immunotherapy (preclinical; early-phase human trials ongoing)
• Musculoskeletal system: Preliminary in vitro evidence for pro-osteogenic effects (no clinical data)

Common Forms and Preparations

In the dietary supplement and functional food sectors, organisms described as "Lactobacillus lactis" (encompassing both L. delbrueckii subsp. lactis and Lactococcus lactis) are encountered in the following forms:

• Fermented dairy foods: Yogurt, cheese (matured and unripened), sour cream, buttermilk, kefir, and fermented butter are the primary natural dietary matrices in which these organisms are consumed. Fermented milk, cheese, yogurt, and kefir are primary sources of these probiotic organisms.
• Freeze-dried (lyophilized) probiotic powders: Cell concentrates are lyophilized following standard procedures; colony-forming units per gram of probiotic powder are determined using serial dilution methods. These are encapsulated or provided in sachets for dietary supplement use.
• Live biotherapeutic products (LBPs): Pharmaceutical-grade preparations such as GEN-001 (containing L. lactis at more than 1 × 10¹¹ CFU per container) are under investigation as drug products in oncology and immunology, distinct from conventional food supplements.
• Fermented non-dairy foods: Lactococcus lactis is also isolated from fermented vegetables (including kimchi), fermented meat, and plant-based fermented products. The species has been isolated from a broad range of habitats including dairy products, fermented meat, fish, vegetables and cereals, sewage, and various human body sites.

Dosages Reported in Studies

The following doses appear in the peer-reviewed clinical and preclinical literature; they are reported exactly as stated in the cited sources and should not be interpreted as clinical recommendations:

• Cognitive function RCT (L. delbrueckii subsp. lactis CKDB001): 5.0 × 10⁹ CFU/day administered orally for 12 weeks in adults aged 55–80 years with mild cognitive impairment.
• Metabolic/obesity mouse model (CKDB001): 1 × 10⁹ CFU in 200 µL sterile phosphate-buffered saline, administered daily via oral gavage for 12 weeks.
• Metabolic mouse model (CKDB001 — second study): 1.0 × 10⁹ CFU per mouse per day in phosphate-buffered saline.
• Oncology live biotherapeutic (GEN-001): More than 1 × 10¹¹ CFU per container (dose escalation study; exact human dosing tiers are defined within the Phase I protocol).

Regulatory and Safety Status

Lactococcus lactis has been granted Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) and enjoys Generally Recognized as Safe (GRAS) status in the United States, based on its traditional usage in food fermentation.

Since LAB have been used for centuries in food production and fermentation without posing health risks, the FDA has classified the majority of LAB as GRAS at the strain level. QPS status was also granted by EFSA to the majority of LAB genera at the species level, including Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, and Streptococcus thermophilus.

Lactococcus lactis has long been used in dairy product fermentation and has a GRAS designation by the FDA. This Gram-positive bacterium lacks endotoxin, which causes endotoxic shock, and has been demonstrated to be a safe delivery system.

L. lactis can pass through the gastrointestinal tract and deliver desired products to the gut but is unable to colonize it.

Safety Considerations: Factual and Source-Backed

General Safety Profile

Safety assessment of Lactococcus lactis IDCC 2301 using in vitro and in vivo assays — including antibiotic resistance, hemolytic activity, toxin production, infectivity, and metabolic activity in immunocompromised animals — demonstrated susceptibility to nine antibiotics suggested by EFSA. Whole-genome analysis revealed no toxigenic genes and no harbored antibiotic resistance. Moreover, this strain showed neither hemolytic nor β-glucuronidase activity.

Antibiotic Resistance Gene Transfer: A Noted Concern

The food chain has been recognized as a key route of antibiotic-resistant bacteria transmission between animals and humans. Lactic acid bacteria could act as a reservoir of transferable antibiotic resistance genes, and LAB strains intended to be used as feed additives or probiotics should be monitored for their safety in this regard. There has been increasing attention to acquired resistance to antimicrobials among LAB strains, as LAB are considered a reservoir of resistance genes that can be transferred to pathogenic bacteria, leading to the spread of antibiotic resistance among pathogens and complicating the treatment of infections. Strain-by-strain safety assessment is therefore important.

Rare Pathogenicity Reports

Lactococcus lactis is a globally recognized safe microorganism for the regulation of intestinal microecological balance and improving host immune performance. However, pathogenic L. lactis has been isolated from clinical cases, including endocarditis in human patients as well as cases involving blood and urine samples, in addition to veterinary contexts. These events are uncommon and appear largely confined to immunocompromised hosts or specific veterinary settings.

EFSA Safety Evaluation Requirements

Newly isolated probiotic strains need to be characterized in terms of multiple safety aspects to ensure they are safe for human consumption. An FAO/WHO working group has suggested that consequence tests — including metabolic activities, antibiotic resistance, toxin production, hemolytic activities, infectivity in immunocompromised animal models, side effects in humans, and adverse outcomes in consumers — are needed to assess the characteristics of probiotic strains and establish safety guidelines.

Clinical Trial Safety Data

In the only published human RCT specifically using L. delbrueckii subsp. lactis CKDB001, safety assessments indicated the supplement was safe and well-tolerated at 5.0 × 10⁹ CFU/day for 12 weeks, with no clinically relevant changes in laboratory findings or adverse events reported.

Genetically Modified Strains

Some research applications involve genetically engineered L. lactis strains, such as those modified to overexpress GABA or therapeutic proteins. Although the use of genetically modified organisms in humans and animals adds possible safety concerns, they have been used safely in both in some contexts. Regulatory frameworks for such engineered strains differ from those governing unmodified food-derived isolates and are beyond standard dietary supplement regulation.

Summary of Evidence Strength

The body of evidence supporting health claims for organisms described as "Lactobacillus lactis" varies substantially by application area:

• Food safety / fermentation technology: Extensive, well-established evidence; the organisms are foundational to global dairy and fermented food industries.
• Antimicrobial activity (bacteriocins, including nisin): Strong in vitro and food-application evidence; limited direct human clinical evidence for therapeutic antimicrobial use.
• Gut health and anti-inflammatory effects: Compelling preclinical evidence (animal models, in vitro); human clinical data in gastroenterology are lacking for these specific organisms.
• Cognitive function (MCI): A single positive RCT (n=100, 12 weeks) for L. delbrueckii subsp. lactis CKDB001; results are promising but preliminary.
• Metabolic health (obesity, blood glucose): Preclinical animal data only.
• Oncology: Preclinical cell-line and animal data; Phase I human trials initiated; no efficacy data published from human trials as of mid-2026.
• Bone metabolism: In vitro only; no in vivo or clinical data.

References

• NCBI Taxonomy Browser: Lactobacillus delbrueckii subsp. lactis (Taxonomy ID: 29397)
• Zheng et al. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera. International Journal of Systematic and Evolutionary Microbiology. Microbiology Society.
• Dymarska et al. (2024). Lactococcus lactis in Dairy Fermentation — Health-Promoting and Probiotic Properties. Fermentation, 10(1), 16. MDPI.
• Kelly et al. (2014). From field to fermentation: The origins of Lactococcus lactis and its domestication to the dairy environment. International Journal of Food Microbiology. ScienceDirect.
• Lv et al. (2020). Fermentation Characteristics of Lactococcus lactis subsp. lactis Isolated From Naturally Fermented Dairy Products. Frontiers in Microbiology.
• Abouelela et al. (2025). Lactobacillus delbrueckii: A Functional Powerhouse in Dairy Fermentation and Emerging Probiotic Applications. PubMed.
• Umu et al. (2022). Genomic Characterization of Lactobacillus delbrueckii Strains with Probiotics Properties. Frontiers in Bioinformatics. PMC.
• Kim et al. (2024). Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice. Nutrients, 16(24), 4260. MDPI.
• Kim et al. (2025). Modulation of Gut Microbial Composition by Lactobacillus delbrueckii subsp. lactis CKDB001 in High-Fat-Diet-Induced Obese Mice. Nutrients, 17(13), 2251. MDPI.
• Baek et al. (2025). Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients, 17(20), 3313. PMC / NIH.
• Lotfiani et al. (2024). Potential probiotic Lactobacillus delbrueckii subsp. lactis KUMS-Y33 suppresses adipogenesis and promotes osteogenesis in human adipose-derived mesenchymal stem cells. Scientific Reports. Nature.
• Kim et al. (2022). Live Biotherapeutic Lactococcus lactis GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. Cancers, 14(17), 4083. PMC.
• ClinicalTrials.gov: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors (NCT04601402).
• Souid et al. (2021). GABA-Producing Lactococcus lactis Strains Isolated from Camel's Milk as Starters for the Production of GABA-Enriched Cheese. Foods, 10(3), 633. MDPI.
• Carre et al. (2022). Lactococcus lactis NCDO2118 exerts visceral antinociceptive properties in rat via GABA production in the gastro-intestinal tract. eLife.
• Pan et al. (2025). GABA-producing Lactococcus lactis alleviates gut dysfunction and neurobehavioral abnormalities associated with irritable bowel syndrome. Microbiome Research Reports. PMC.
• Lee et al. (2024). Genetically engineered Lactococcus lactis strain constitutively expresses GABA-producing genes and produces high levels of GABA. Letters in Applied Microbiology. Oxford Academic.
• Bartkiene et al. (2022). Health-Promoting Nature of Lactococcus lactis IBB109 and IBB417 Strains Exhibiting Proliferation Inhibition and Stimulation of Interleukin-18 Expression in Colorectal Cancer Cells. PMC.
• Oh et al. (2022). Safety evaluation of Lactococcus lactis IDCC 2301 isolated from homemade cheese. PMC / NIH.
• Gad et al. (2021). Antimicrobial Susceptibility of Lactic Acid Bacteria Strains of Potential Use as Feed Additives. Frontiers in Veterinary Science.
• Moulay et al. (2025). Probiotic potential and bioactive properties of Lactococcus lactis MSH-08 isolates from fermented dairy products. Future Foods. ScienceDirect.
• Musa et al. (2017). Lactococcus lactis Strain A5 Producing Nisin-like Bacteriocin Active against Gram Positive and Negative Bacteria. PMC / NIH.
• Vente et al. (2022). Recombinant production of the lantibiotic nisin using Corynebacterium glutamicum in a two-step process. PMC / NIH.
• Khan et al. (2025). Comprehensive evaluation of bioactive properties and metabolomic profiling of probiotic bacteria Lactococcus lactis (MKL8). PMC / NIH.
• Li et al. (2023). Lactococcus lactis, a bacterium with probiotic functions and pathogenicity. PubMed.
• Fusco et al. (2024). Probiotic Properties of Lactococcus lactis Strains Isolated from Natural Whey Starter Cultures. Foods, 13(6), 957. MDPI.